More on AstraZeneca Oxford University COVID-19 vaccine resumption

Drugs giant AstraZeneca confirmed on Saturday that it had resumed a COVID-19 vaccine trial after getting the all-clear from British regulators.

"Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so," AstraZeneca said in a statement.

The late-stage trials of the experimental vaccine were suspended this week after an illness in a study subject in Britain.

The company said investigation has completed but it could not disclose further medical information.

"AstraZeneca and the University of Oxford, as the trial sponsor, cannot disclose further medical information. All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards," read the statement.